[Cardiac troponins and left ventricular hypertrophy in hemodialysis patients]

Dejan Petrović1, Radmila Obrenović, Milan Radovanović

  • 1Klinika za urologiju i nefrologiju, Odeljenje hemodijalize, Klinicki centar Kragujevac, Kragujevac. aca96@Eunet.yu

Medicinski Pregled
|October 22, 2008
PubMed

Insights

Left ventricular hypertrophy in hemodialysis patients is linked to elevated cardiac troponin T levels. This finding suggests troponin T may help assess hypertrophy in stable patients without acute coronary syndrome.

Area of Science:

  • Nephrology
  • Cardiology
  • Biochemistry

Background:

  • Cardiovascular diseases are a leading cause of death in hemodialysis patients.
  • Left ventricular hypertrophy (LVH) is a significant predictor of cardiovascular events in this population.
  • Cardiac troponins (cTnT, cTnI) are biomarkers of myocardial injury.

Purpose of the Study:

  • To investigate the relationship between left ventricular hypertrophy and serum cardiac troponin concentrations in hemodialysis patients.
  • To determine if cardiac troponin T can serve as an indicator of LVH.

Main Methods:

  • 115 hemodialysis patients were categorized into four groups based on echocardiographic findings: concentric LVH, eccentric LVH, left ventricular dilatation, and normal morphology.
  • Serum troponin T levels were measured in all patient groups.
  • Statistical analysis was performed to compare troponin T levels across groups.

Main Results:

  • Patients with concentric LVH exhibited significantly higher serum troponin T levels compared to those with normal morphology (p<0.05).
  • Patients with eccentric LVH showed highly significantly greater serum troponin T concentrations than patients with normal morphology (p<0.01).
  • Elevated troponin T levels were observed in patients with left ventricular dilatation compared to the normal morphology group.

Conclusions:

  • Serum cardiac troponin T concentration can be utilized to estimate left ventricular hypertrophy in clinically stable hemodialysis patients.
  • This estimation is valid in the absence of acute coronary syndrome.
  • Troponin T may serve as a non-invasive marker for assessing cardiac remodeling in hemodialysis patients.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...